AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36227771 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 36227781 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal Short Chain Fatty Acids (SCFAs)
Number of subjects: 64
Study 36227781 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetate
Number of subjects: 64
Study 36227781 — intervention group
Group type: EXPERIMENTAL
Intervention: Total SCFAs
Number of subjects: 64
Study 36227828 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning-based image registration method
Number of subjects: 118
Study 36227839 — intervention group
Group type: EXPERIMENTAL
Intervention: Active and passive case finding for wound management study
Number of subjects: 3842
Study 36227839 — intervention group
Group type: EXPERIMENTAL
Intervention: Buruli ulcer prevalence
Number of subjects: 3842
Study 36227844 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based wound management (C)
Number of subjects: 561
Study 36227844 — intervention group
Group type: EXPERIMENTAL
Intervention: Health centre wound management (HC)
Number of subjects: 561
Study 36227844 — intervention group
Group type: EXPERIMENTAL
Intervention: District hospital wound management (DH)
Number of subjects: 561
Study 36227844 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute wound management
Number of subjects: 561
Study 36227844 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic wound management
Number of subjects: 561
Study 36227844 — intervention group
Group type: EXPERIMENTAL
Intervention: Recapturing of wounds
Number of subjects: 561
Study 36227860 — intervention group
Group type: EXPERIMENTAL
Intervention: Promoting First Relationships (PFR) intervention
Number of subjects: 0
Study 36228064 — intervention group
Group type: EXPERIMENTAL
Intervention: Clock-drawing test (abnormal)
Number of subjects: 1448
Study 36228064 — intervention group
Group type: EXPERIMENTAL
Intervention: Clock-drawing test (normal)
Number of subjects: 1448
Study 36228064 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic characteristics (female, 8th grade education or less)
Number of subjects: 1448
Study 36228060 — intervention group
Group type: EXPERIMENTAL
Intervention: More effective facilitators
Number of subjects: 1630
Study 36228060 — intervention group
Group type: COMPARATOR
Intervention: Less effective facilitators
Number of subjects: 1630
Study 36228112 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical bexarotene
Number of subjects: 0
Study 36228130 — intervention group
Group type: EXPERIMENTAL
Intervention: DigiCOVID protocol (remote teletherapy sessions)
Number of subjects: 122
Study 36228130 — intervention group
Group type: EXPERIMENTAL
Intervention: DigiCOVID protocol (8 teletherapy sessions)
Number of subjects: 122
Study 36228643 — intervention group
Group type: EXPERIMENTAL
Intervention: UCART19
Number of subjects: 25
Study 36228644 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose carboplatin (AUC 7) followed by involved-node radiotherapy (30 Gy in 15 fractions for stage IIA and 36 Gy in 18 fractions for stage IIB)
Number of subjects: 116
Study 36228644 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose carboplatin (AUC 7) followed by involved-node radiotherapy
Number of subjects: 116
Study 36228700 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal time of 6 minutes
Number of subjects: 1142
Study 36228700 — intervention group
Group type: EXPERIMENTAL
Intervention: Every 1-minute increase in withdrawal time
Number of subjects: 1142
Study 36228746 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab with 70 Gy intensity modulated radiation therapy and weekly cisplatin (arm 1)
Number of subjects: 39
Study 36228746 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab with 70 Gy intensity modulated radiation therapy and every 3-week cisplatin (arm 2)
Number of subjects: 39
Study 36228746 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab with 70 Gy intensity modulated radiation therapy and cetuximab (arm 3)
Number of subjects: 39
Study 36228746 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab alone for platinum-ineligible patients (arm 4)
Number of subjects: 39
Study 36228746 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant nivolumab
Number of subjects: 39
Study 36228746 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (all arms)
Number of subjects: 39
Study 36229024 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Actiregularis, 5×10^6) added to the diet of mothers once daily for 15 days
Number of subjects: 0
Study 36229024 — intervention group
Group type: COMPARATOR
Intervention: Control group (no probiotics)
Number of subjects: 0
Study 36229089 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan (Sac/Val) - Low Dose (112 mg)
Number of subjects: 794
Study 36229089 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan (Sac/Val) - Moderate Dose (342 mg)
Number of subjects: 794
Study 36229089 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan (Sac/Val) - High Dose (379 mg)
Number of subjects: 794
Study 36229089 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan (Sac/Val) - All doses
Number of subjects: 794
Study 36229091 — intervention group
Group type: EXPERIMENTAL
Intervention: CHIP carriers
Number of subjects: 446
Study 36229091 — intervention group
Group type: COMPARATOR
Intervention: Non-CHIP patients
Number of subjects: 446
Study 36229153 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-held ultrasound (HUD) examinations with automatic decision-making software for ejection fraction (autoEF)
Number of subjects: 166
Study 36229153 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-held ultrasound (HUD) examinations with automatic decision-making software for mitral annular plane systolic excursion (autoMAPSE)
Number of subjects: 166
Study 36229153 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-held ultrasound (HUD) examinations by novices
Number of subjects: 166
Study 36229153 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-held ultrasound (HUD) examinations by experts
Number of subjects: 166
Study 36229153 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic measurements of autoEF and autoMAPSE
Number of subjects: 166
Study 36229188 — intervention group
Group type: EXPERIMENTAL
Intervention: presymptomatic MS
Number of subjects: 177
Study 36229188 — intervention group
Group type: COMPARATOR
Intervention: healthy controls (HCs)
Number of subjects: 177
Study 36229329 — intervention group
Group type: EXPERIMENTAL
Intervention: CLES (Remote ex vivo lung perfusion)
Number of subjects: 115
Study 36229329 — intervention group
Group type: COMPARATOR
Intervention: Control (conventional static cold-preserved lungs)
Number of subjects: 115
Study 36229547 — intervention group
Group type: EXPERIMENTAL
Intervention: TOGETHER-YA intervention
Number of subjects: 11
Study 36229741 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow diameter implants in T2DM patients
Number of subjects: 31
Study 36229741 — intervention group
Group type: COMPARATOR
Intervention: Narrow diameter implants in normo-glycemic patients
Number of subjects: 31
Study 36229741 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow diameter implants (general)
Number of subjects: 31
Study 36229790 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart Triage digital triaging platform
Number of subjects: 15
Study 36229853 — intervention group
Group type: EXPERIMENTAL
Intervention: DZD2269 (A2aR antagonist)
Number of subjects: 0
Study 36229853 — intervention group
Group type: EXPERIMENTAL
Intervention: DZD2269 (A2aR antagonist) in combination with immune checkpoint inhibitors, radiotherapy, or chemotherapy
Number of subjects: 0
Study 36230640 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified NILG-AML 01/00 protocol (high dose of ARAC plus idarubicin consolidation)
Number of subjects: 171
Study 36230640 — intervention group
Group type: EXPERIMENTAL
Intervention: NPM1-mutated patients
Number of subjects: 171
Study 36230640 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated ITD patients
Number of subjects: 171
Study 36230640 — intervention group
Group type: EXPERIMENTAL
Intervention: NPM1-co-mutated patients with ITD or TKD mutation
Number of subjects: 171
Study 36230640 — intervention group
Group type: EXPERIMENTAL
Intervention: NPM1 wild-type and FLT3-mutated patients
Number of subjects: 171
Study 36230669 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral swab assessment before RT
Number of subjects: 152
Study 36230669 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumour site and lymphocytopenia as risk factors
Number of subjects: 152
Study 36231265 — intervention group
Group type: COMPARATOR
Intervention: NHF data
Number of subjects: 0
Study 36231265 — intervention group
Group type: COMPARATOR
Intervention: CHA2DS2VASc score from NHF
Number of subjects: 0
Study 36231265 — intervention group
Group type: EXPERIMENTAL
Intervention: CHA2DS2VASc score from IHR
Number of subjects: 0
Study 36231487 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants (vitamins A, E, D) and microelements (Cu, Se, Zn) levels
Number of subjects: 80
Study 36231487 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper (Cu) levels
Number of subjects: 80
Study 36231487 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper (Cu) and Zinc (Zn) levels
Number of subjects: 80
Study 36231670 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased physical activity (58% women, 55% men at the beginning; 56% women, 53% men at the end)
Number of subjects: 32409
Study 36231670 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased physical activity (20% women, 14% men at the beginning; 23% women, 18% men at the end)
Number of subjects: 32409
Study 36231670 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for decreased physical activity
Number of subjects: 32409
Study 36231670 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for increased physical activity
Number of subjects: 32409
Study 36231670 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity changes
Number of subjects: 32409
Study 36231682 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonometry data analysis
Number of subjects: 6
Study 36231682 — intervention group
Group type: EXPERIMENTAL
Intervention: Various techniques (analysis of variance, network correlation structure analysis, multinomial logistic regression, discrimination analysis)
Number of subjects: 6
Study 36231682 — intervention group
Group type: EXPERIMENTAL
Intervention: Feature selection methods
Number of subjects: 6
Study 36231712 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month multicomponent training (MCT)
Number of subjects: 106
Study 36231712 — intervention group
Group type: COMPARATOR
Intervention: Usual lifestyle (Control group)
Number of subjects: 106
Study 36231817 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible Cognitive Restraint Scale
Number of subjects: 620
Study 36231817 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid Cognitive Restraint Scale
Number of subjects: 620
Study 36232227 — intervention group
Group type: EXPERIMENTAL
Intervention: Support system and resilience
Number of subjects: 1121
Study 36232227 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher resilience and support system
Number of subjects: 1121
Study 36232227 — intervention group
Group type: EXPERIMENTAL
Intervention: Family distress
Number of subjects: 1121
Study 36232227 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived university support
Number of subjects: 1121
Study 36232227 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferred sources of support
Number of subjects: 1121
Study 36232227 — intervention group
Group type: EXPERIMENTAL
Intervention: University support services
Number of subjects: 1121
Study 36233712 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (6 weekly sessions)
Number of subjects: 47
Study 36233712 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 47
Study 36233717 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced hypertension
Number of subjects: 303
Study 36233717 — intervention group
Group type: COMPARATOR
Intervention: Invasive endovascular treatment
Number of subjects: 303
Study 36235639 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed sources containing sugar-sweetened beverages (SSBs)
Number of subjects: 64
Study 36235639 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit, 100% fruit juice, sweetened soy beverage, dark chocolate
Number of subjects: 64
Study 36237146 — intervention group
Group type: EXPERIMENTAL
Intervention: NINDS-CSN cognitive battery (executive functioning, attention, processing speed)
Number of subjects: 110
Study 36237146 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitively impaired patients
Number of subjects: 110
Study 36237618 — intervention group
Group type: EXPERIMENTAL
Intervention: TUDCA
Number of subjects: 320
Study 36237618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study 36237908 — intervention group
Group type: EXPERIMENTAL
Intervention: Zilver PTX drug-eluting stent (DES)
Number of subjects: 178
Study 36237914 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors (SGLT2-i)
Number of subjects: 646
Study 36237914 — intervention group
Group type: COMPARATOR
Intervention: Non-SGLT2 inhibitors (control group)
Number of subjects: 646
Study 36238450 — intervention group
Group type: EXPERIMENTAL
Intervention: IOE supplementation
Number of subjects: 80
Study 36238450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 36238465 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal-infant biological samples (blood, feces, saliva, urine, and breast milk) collected during pregnancy and the first year of life.
Number of subjects: 0
Study 36238568 — intervention group
Group type: EXPERIMENTAL
Intervention: Avatrombopag
Number of subjects: 0
Study 36238712 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth tool (MoVeUP)
Number of subjects: 0
Study 36238712 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard approach)
Number of subjects: 0
Study 36238717 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1283
Number of subjects: 0
Study 36238717 — intervention group
Group type: COMPARATOR
Intervention: mRNA-1273
Number of subjects: 0
Study 36239199 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan 15 mg t.i.d.
Number of subjects: 194
Study 36239199 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide inhaler 20 µg 2 puffs t.i.d.
Number of subjects: 194
Study 36239199 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of honey t.i.d.
Number of subjects: 194
Study 36239199 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 194
Study 36239473 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD) 30 mg/m2 on day 1 combined with ifosfamide (IFO) 1.8 g/m2 on days 1-5 every 21 days for up to six cycles
Number of subjects: 69
Study 36239473 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD) combined with ifosfamide (IFO)
Number of subjects: 69
Study 36239473 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploratory biomarker analysis
Number of subjects: 69
Study 36239625 — intervention group
Group type: EXPERIMENTAL
Intervention: TORS
Number of subjects: 44
Study 36239625 — intervention group
Group type: COMPARATOR
Intervention: RT
Number of subjects: 44
Study 36239788 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 937
Study 36239788 — intervention group
Group type: COMPARATOR
Intervention: No chemotherapy (Control)
Number of subjects: 937
Study 36239788 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy and No chemotherapy
Number of subjects: 937
Study 36239858 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor Treating Fields (TTFields) therapy (200 kHz)
Number of subjects: 0
Study 36239858 — intervention group
Group type: COMPARATOR
Intervention: Physicians' choice standard-of-care (PC-SOC)
Number of subjects: 0
Study 36239955 — intervention group
Group type: EXPERIMENTAL
Intervention: Email reminders
Number of subjects: 0
Study 36239955 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized telephone outreach
Number of subjects: 0
Study 36239955 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of both email reminders and personalized telephone outreach
Number of subjects: 0
Study 36240004 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention (InCharge Health app)
Number of subjects: 55
Study 36240084 — intervention group
Group type: EXPERIMENTAL
Intervention: Idiopathic Intracranial Hypertension (IIH) participants undergoing weight loss intervention for disease remission
Number of subjects: 0
Study 36240084 — intervention group
Group type: COMPARATOR
Intervention: Control group (sex-matched, age-matched, and BMI-matched)
Number of subjects: 0
Study 36240089 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive IADL impairment (n = 37) at baseline
Number of subjects: 268
Study 36240089 — intervention group
Group type: COMPARATOR
Intervention: PD-MCI
Number of subjects: 268
Study 36240089 — intervention group
Group type: COMPARATOR
Intervention: No cognitive impairment
Number of subjects: 268
Study 36240089 — intervention group
Group type: COMPARATOR
Intervention: Dementia
Number of subjects: 268
Study 36240181 — intervention group
Group type: EXPERIMENTAL
Intervention: Complicated acute appendicitis
Number of subjects: 118
Study 36240181 — intervention group
Group type: COMPARATOR
Intervention: Uncomplicated acute appendicitis
Number of subjects: 118
Study 36240296 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic HSCT
Number of subjects: 163
Study 36240296 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic HSCT in patients with graft rejection (12%, N = 20)
Number of subjects: 163
Study 36240323 — intervention group
Group type: EXPERIMENTAL
Intervention: β-hydroxybutyrate (βOHB) infusion
Number of subjects: 8
Study 36240323 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 8
Study 36240452 — intervention group
Group type: EXPERIMENTAL
Intervention: GROW intervention (online parenting-skills program with six online learning modules and videoconference meetings with a coach)
Number of subjects: 72
Study 36240452 — intervention group
Group type: EXPERIMENTAL
Intervention: GROW intervention
Number of subjects: 72
Study 36240755 — intervention group
Group type: EXPERIMENTAL
Intervention: Fourth dose of BNT162b2 vaccine
Number of subjects: 80
Study 36240755 — intervention group
Group type: EXPERIMENTAL
Intervention: B cell-depleting therapies within 12 months before vaccination
Number of subjects: 80
Study 36240755 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakthrough infections after vaccination
Number of subjects: 80
Study 36241629 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab plus cisplatin and pemetrexed
Number of subjects: 18
Study 36241696 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV) and DHAP followed by autologous stem-cell transplantation (ASCT)
Number of subjects: 65
Study 36241696 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV) and DHAP
Number of subjects: 65
Study 36241843 — intervention group
Group type: EXPERIMENTAL
Intervention: cSAH patients with suspected CAA
Number of subjects: 50
Study 36241982 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 ml subcutaneous injection of SPIO with 30-s massage
Number of subjects: 6
Study 36241982 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 ml intracutaneous injection of SPIO with 2-min massage
Number of subjects: 6
Study 36242017 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular reading activities
Number of subjects: 459
Study 36242017 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher education levels (more than 13 years)
Number of subjects: 459
Study 36242017 — intervention group
Group type: EXPERIMENTAL
Intervention: More reading activities in low education groups (less than 12 years)
Number of subjects: 459
Study 36242017 — intervention group
Group type: COMPARATOR
Intervention: Non-reading group
Number of subjects: 459
Study 36242033 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall high HrQoL (47% of sample)
Number of subjects: 600
Study 36242033 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressively decreasing HrQoL (32%)
Number of subjects: 600
Study 36242033 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall low HrQoL (8%)
Number of subjects: 600
Study 36242033 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetric decline in HrQoL (13%)
Number of subjects: 600
Study 36242576 — intervention group
Group type: EXPERIMENTAL
Intervention: EF-D group
Number of subjects: 57
Study 36242576 — intervention group
Group type: COMPARATOR
Intervention: EF-N group
Number of subjects: 57
Study 36242633 — intervention group
Group type: EXPERIMENTAL
Intervention: High angiogenic habitat
Number of subjects: 69
Study 36242633 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate angiogenic habitat
Number of subjects: 69
Study 36242633 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative cerebral blood volume (rCBV)
Number of subjects: 69
Study 36242633 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular habitats combining high and intermediate angiogenic habitats
Number of subjects: 69
Study 36242633 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular habitats stratification
Number of subjects: 69
Study 36242680 — intervention group
Group type: EXPERIMENTAL
Intervention: Redo Bariatric Surgery (RBS)
Number of subjects: 529
Study 36242680 — intervention group
Group type: EXPERIMENTAL
Intervention: One Anastomosis Gastric Bypass (OAGB) as RBS
Number of subjects: 529
Study 36242700 — intervention group
Group type: EXPERIMENTAL
Intervention: metastasis-directed therapy
Number of subjects: 0
Study 36242700 — intervention group
Group type: EXPERIMENTAL
Intervention: intensified hormonal treatments
Number of subjects: 0
Study 36242700 — intervention group
Group type: EXPERIMENTAL
Intervention: modern imaging (e.g. PSMA PET/CT)
Number of subjects: 0
Study 36242700 — intervention group
Group type: EXPERIMENTAL
Intervention: ablative local treatment
Number of subjects: 0
Study 36242700 — intervention group
Group type: EXPERIMENTAL
Intervention: newest systemic therapies
Number of subjects: 0
Study 36242742 — intervention group
Group type: EXPERIMENTAL
Intervention: Debridement, antibiotics and implant retention (DAIR) with rifampicin
Number of subjects: 120
Study 36242742 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosthesis removal
Number of subjects: 120
Study 36242742 — intervention group
Group type: COMPARATOR
Intervention: Debridement, antibiotics and implant retention (DAIR) without rifampicin
Number of subjects: 120